Sunpointe’s Xeris Biopharma Holdings XERS Stock Holding History

Sunpointe’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,000	Closed	-$171K	–	285
2025 Q3	$171K	Hold	21,000	–	–	0.06%	247
2025 Q2	$98.1K	Hold	21,000	–	–	0.04%	228
2025 Q1	$115K	Hold	21,000	–	–	0.06%	179
2024 Q4	$71.2K	Buy	+21,000	New	+$67.5K	0.04%	187

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sunpointe's XERS Position: Q4 2025 in Review

Sunpointe sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 21,000 shares — an estimated $171K sold.

Sunpointe first reported a position in XERS in Q4 2024 and held it in 4 quarters. The position peaked at $171K in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

Sunpointe reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
Sunpointe sold 21,000 Xeris Biopharma Holdings shares in Q4 2025, an estimated $171K.
Sunpointe first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 4 quarters.
Sunpointe's Xeris Biopharma Holdings position peaked at $171K in Q3 2025.
225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Sunpointe's 13F filing for Q4 2025, filed 23 Jan 2026.